World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   285 records for 179 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4 5 6 7 8 9 10 Last
Recruitment statusMain ID Public TitleDate of Registration
AuthorisedEUCTR2014-002275-28-FI
Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease. 28/10/2014
Not recruitingACTRN12614000995673
A randomized trial of preoperative oral carbohydrates in abdominal surgery
16/09/2014
RecruitingNCT02104245
Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis
28/03/2014
Not recruitingACTRN12613001118796
Intervention with diet rich in two types of dietary fibre on glycemia, adipokines and lipid status in obese pre-diabetic subjects
04/10/2013
Not recruitingACTRN12613001077752
Inter- and Intra-rater Reliability of Ultrasound Imaging of Lumbar Multifidus and Transverse Abdominal Muscles in Subjects with and without Low Back Pain
26/09/2013
Not RecruitingEUCTR2010-022134-89-HU
Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2010-022134-89-SIEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.15/11/2013
AuthorisedEUCTR2010-022134-89-ESEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.01/10/2013
AuthorisedEUCTR2010-022134-89-CZEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/10/2013
AuthorisedEUCTR2010-022134-89-ITEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.20/09/2013
Not RecruitingEUCTR2010-022134-89-NLEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.04/10/2013
Not RecruitingEUCTR2010-022134-89-EEEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.14/10/2013
Not RecruitingEUCTR2010-022134-89-LTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.24/10/2013
Not RecruitingEUCTR2010-022134-89-DKEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.23/01/2014
AuthorisedEUCTR2010-022134-89-ATEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.03/02/2014
AuthorisedEUCTR2010-022134-89-HREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.29/08/2014
AuthorisedEUCTR2010-022134-89-PTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/09/2014
AuthorisedEUCTR2010-022134-89-GREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/01/2014
11/09/2013
Not recruitingACTRN12613000982718
Investigation of alpha-lipoic acid supplementation in patients with schizophrenia
03/09/2013
RecruitingNCT01830647
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum
10/04/2013
AuthorisedEUCTR2012-003647-30-BE
A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003647-30-GBA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).23/10/2012
AuthorisedEUCTR2012-003647-30-ESA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).29/10/2012
AuthorisedEUCTR2012-003647-30-GRA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).14/11/2012
AuthorisedEUCTR2012-003647-30-DEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-LVA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-HUA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-ITA multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)11/01/2013
AuthorisedEUCTR2012-003647-30-ATA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).07/02/2013
AuthorisedEUCTR2012-003647-30-EEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).19/11/2012
AuthorisedEUCTR2012-003647-30-BGA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).10/05/2013
AuthorisedEUCTR2012-003647-30-SKA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).20/02/2014
AuthorisedEUCTR2012-003647-30-PLA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).12/02/2013
AuthorisedEUCTR2012-003647-30-CZA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).28/11/2012
08/10/2012
RecruitingNCT01707992
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
28/09/2012
    
1 2 3 4 5 6 7 8 9 10 Last
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history